What do patients think? new study asks women about their cancer treatment experience
NCT ID NCT07008963
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib plus fulvestrant for at least one week. Researchers wanted to learn about patients' attitudes toward the dosing schedule and any side effects that affected their ability to stay on treatment. The goal was to gather real-world patient perspectives, not to test the drugs themselves.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Redwood Shores, California, 94065, United States
Conditions
Explore the condition pages connected to this study.